NYSEAMERICAN:MTNB

Matinas Biopharma (MTNB) Stock Price, News & Analysis

Matinas Biopharma logo
$0.91 +0.05 (+6.35%)
As of 04:10 PM Eastern

About Matinas Biopharma Stock (NYSEAMERICAN:MTNB)

Advanced

Key Stats

Today's Range
$0.87
▼
$0.91
50-Day Range
$0.86
▼
$3.08
52-Week Range
$0.81
▼
$17.40
Volume
5,849 shs
Average Volume
55,963 shs
Market Capitalization
$891.80 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Matinas BioPharma is a biopharmaceutical company focused on developing medicines using its lipid nanocrystal (LNC) delivery technology. The platform is designed to help deliver drugs that can be difficult to administer or absorb, including through oral formulations.

The company’s development programs have included MAT2203, an oral formulation of amphotericin B studied for serious fungal infections, and MAT2501, an oral formulation of amikacin investigated for difficult-to-treat bacterial infections. These programs have been intended to offer alternatives to conventional routes of administration.

Matinas has also explored its LNC platform for delivering other types of therapeutics. Its work has primarily centered on drug development rather than selling a broad range of commercial medicines.

AI Generated. May Contain Errors.

Matinas Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

MTNB MarketRank™: 
1.47046952778 of 5 stars

Matinas Biopharma scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Matinas Biopharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Matinas Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Matinas Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Matinas Biopharma has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.80% of the float of Matinas Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Matinas Biopharma has a short interest ratio ("days to cover") of 0.65, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Matinas Biopharma has recently decreased by 28.10%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Matinas Biopharma does not currently pay a dividend.

  • Dividend Growth

    Matinas Biopharma does not have a long track record of dividend growth.

  • News Sentiment

    Matinas Biopharma has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Matinas Biopharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Matinas Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.60% of the stock of Matinas Biopharma is held by insiders.

  • Percentage Held by Institutions

    11.77% of the stock of Matinas Biopharma is held by institutions.

  • Read more about Matinas Biopharma's insider trading history.
Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MTNB Stock News Headlines

Your book is inside
Blane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn $100 Options Into $1,000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.tc pixel
See More Headlines

MTNB Stock Analysis - Frequently Asked Questions

Matinas Biopharma's stock was trading at $8.79 at the start of the year. Since then, MTNB stock has decreased by 89.6% and is now trading at $0.91.

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings data on Monday, November, 16th. The company reported ($9.35) earnings per share (EPS) for the quarter.

Matinas Biopharma's stock reverse split on the morning of Monday, September 28th 2026.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, September 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include SCYNEXIS (SCYX), Tesla (TSLA), Viking Therapeutics (VKTX), Kushco (KSHB), Oncobiologics (OTLK), NIO (NIO) and Bionano Genomics (BNGO).

Company Calendar

Last Earnings
11/16/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSEAMERICAN:MTNB
Previous Symbol
NYSE:MTNB
CIK
1582554
Fax
N/A
Employees
2
Year Founded
2011

Profitability

EPS (Trailing Twelve Months)
($3.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.35 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-215.21%
Return on Assets
-125.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.85
Quick Ratio
0.85

Sales & Book Value

Annual Sales
$1.10 million
Price / Sales
0.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.30 per share
Price / Book
0.08

Miscellaneous

Outstanding Shares
980,000
Free Float
935,000
Market Cap
$891.80 thousand
Optionable
N/A
Beta
2.24

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NYSEAMERICAN:MTNB) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners